US HB7032 | 2021-2022 | 117th Congress
Status
Spectrum: Partisan Bill (Democrat 2-0)
Status: Introduced on March 9 2022 - 25% progression, died in committee
Action: 2022-03-10 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on March 9 2022 - 25% progression, died in committee
Action: 2022-03-10 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Summary
To amend section 505(j) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)) with respect to a process to inform persons submitting an abbreviated application for a new drug whether the new drug is qualitatively or quantitatively the same as a listed drug, and for other purposes.
Title
Increasing Transparency in Generic Drug Applications Act of 2022
Sponsors
| Rep. Ann Kuster [D-NH] | Rep. Kim Schrier [D-WA] |
History
| Date | Chamber | Action |
|---|---|---|
| 2022-03-10 | House | Referred to the Subcommittee on Health. |
| 2022-03-09 | House | Referred to the House Committee on Energy and Commerce. |
| 2022-03-09 | House | Introduced in House |
Same As/Similar To
HB7667 (Related) 2022-06-09 - Received in the Senate.
SB4338 (Related) 2022-05-26 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
SB4338 (Related) 2022-05-26 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Subjects
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/117th-congress/house-bill/7032/all-info |
| Text | https://www.congress.gov/117/bills/hr7032/BILLS-117hr7032ih.pdf |
